Section 153C requires person-specific search authority and year-specific incriminating material for unabated assessments while preventing unsupported ...
Equivalent-value attachment can reach pre-existing assets, but jointly owned property remains protected beyond the accused's attributable proceeds of ...
Page of 4891
Press 'Enter' after typing page number.
941 to 960 of 97820 Results
❮
❯
❯❯
0 / 200
Expand Note
Add to Folder
No Folders have been created
+
Are you sure you want to delete "My most important" ?
Bulk drugs and active pharmaceutical ingredients qualify as "all drugs and medicines" for the specified IGST rate entry because the inclusive statutory definition of "drug" covers substances used as drug components. Their use in manufacture, testing, clinical trials, bioavailability studies or bioequivalence studies does not change their character as drugs. The description-based entry covers APIs even where classified under chemical chapters, and prevails over general chapter-based entries for organic and inorganic chemicals. Imports of bulk drugs or APIs therefore attract IGST at 5% under the relevant rate entry, unless they fall within the separate nil-rated entry.
Bulk drugs and active pharmaceutical ingredients qualify as "all drugs and medicines" for the specified IGST rate entry because the inclusive statutory definition of "drug" covers substances used as drug components. Their use in manufacture, testing, clinical trials, bioavailability studies or bioequivalence studies does not change their character as drugs. The description-based entry covers APIs even where classified under chemical chapters, and prevails over general chapter-based entries for organic and inorganic chemicals. Imports of bulk drugs or APIs therefore attract IGST at 5% under the relevant rate entry, unless they fall within the separate nil-rated entry.
Note: It is a system-generated summary and is for quick reference only.